

1 **Title page**

2 Title: Mapping The Global Landscape Of Chikungunya Rapid Diagnostic Tests: A Scoping

3 Review

4

5 Running title: Chikungunya rapid diagnostic test landscape

6

7 Authors: José Moreira^{1,2}, Patrícia Brasil¹, Sabine Dittrich^{3,4}, André M Siqueira¹

8

9 Affiliations:

10 1.Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de

11 Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil

12 2. Departamento de Ensino e Pesquisa, Instituto Nacional de Cardiologia, Rio de Janeiro,

13 Brasil

14 3.Malaria & Fever department, Foundation for Innovative New Diagnostics, Switzerland,

15 Geneva

16 4. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

17

18 Corresponding author: José Moreira; e-mail: jose.moreira@ini.fiocruz.br; telephone

19 number: +55 (21) 97035-8843; Laboratório de Pesquisa Clínica em Doenças Febris Agudas,

20 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil, 4365

21 –Manguinhos, Rio de Janeiro, Brazil, CEP: 21040-360; Twitter: @j_moreira_

22

23 Keywords: Chikungunya; Diagnostics; Field trial; Review; Guideline; Rapid diagnostic test;

24 Fever

25

26 **Abstract**

27 **Background**

28 Chikungunya virus (CHIKV) is a re-emerging arboviral disease and represents a global health threat because of the
29 unprecedented magnitude of its spread. Diagnostics strategies rely heavily on reverse transcriptase-polymerase chain
30 reaction (RT-PCR) and antibody detection by Enzyme-linked Immunosorbent assay (ELISA). Rapid Diagnostic Tests (RDTs)
31 are available and promise to decentralize testing and increase availability at lower healthcare system levels.

32 **Objectives**

33 We aim to identify the extent of research on CHIKV RDTs, map the global availability of CHIKV RDTs, and evaluate the
34 accuracy of CHIKV RDTs for the diagnosis of CHIKV.

35 **Eligibility criteria**

36 We included studies reporting symptomatic individuals suspected of CHIKV, tested with CHIKV RDTs, against the
37 comparator being a validated laboratory-based RT-PCR or ELISA assay. The primary outcome was the accuracy of the CHIKV
38 RDT when compared with reference assays.

39 **Sources of evidence**

40 Medline, EMBASE, and Scopus were searched from inception to October 13th, 2021. National regulatory agencies
41 (European Medicines Agency, U.S. Food and Drug Administration, and the Brazilian National Health Surveillance Agency)
42 were also searched for registered CHIKV RDTs.

43 **Results**

44 Eighteen studies were included and corresponded to 3722 samples tested with RDTs between 2005-2019. The most
45 development stage of CHIKV RDTs studies was phase I (7/18 studies) and II (7/18 studies). No studies were in phase IV. The
46 countries that manufacturer the most CHIKV RDTs were Brazil ($n=17$), followed by the USA ($n=7$), and India ($n=6$). Neither
47 at EMA nor FDA, registered products were found. Conversely, the ANVISA has approved 23 CHIKV RDTs. Antibody RDTs
48 ($n=43$) predominated and demonstrated sensitivity between 20% and 100%. The sensitivity of the antigen RDTs ranged
49 from 33.3 to 100%.

50 **Conclusions**

51 The landscape of CHIKV RDTs is fragmented and needs coordinated efforts to ensure that patients in CHIKV-endemic areas
52 have access to appropriate RDTs. Further research is crucial to determine the impact of such tests on integrated fever case
53 management and prescription practices for acute febrile patients.

54

55 **Keywords:** Chikungunya; Diagnostics; Field trial; Review; Guideline; Rapid diagnostic test; Fever

56

57

58 **Text**

59 **Introduction**

60 Chikungunya -a re-emerging arboviral disease caused by Chikungunya virus (CHIKV)- is
61 transmitted by mosquitoes of the Aedes species, specifically *A. aegypti*, *A. albopictus*, and *A.*
62 *polynesiensis* [1]. The disease is characterized by the classic triad of debilitating
63 polyarthralgia, high-grade fever, and myalgia [1]. During the past years, we have seen an
64 unprecedented magnitude of the disease spreading across the globe (i.e., 106
65 countries/territories reported autochthonous or travel-related transmission), affecting
66 millions of people in the Americas, Asia, the Indian subcontinent, Europe, and in the Pacific
67 islands [2].

68 One of the challenges imposed by CHIKV has been the correct identification of suspected
69 individuals in the context of co-circulation of other arboviruses that present similarly in
70 tropical regions [3]. Laboratory diagnosis has been mainly focused on either RNA or virus-
71 specific antibody detection through RT-PCR and ELISA technique, respectively. However,
72 such diagnostic technologies require complex instrumentation and are not easy to perform
73 outside sophisticated laboratories in urban settings where trained personnel are available.
74 Therefore, these tests are not accessible or affordable to patients at the lower healthcare
75 system levels, where most CHIKV outbreaks occur. In contrast, rapid diagnostic tests (RDTs)
76 promise to overcome some of these challenges by bridging many gaps along the diagnostic
77 test pathway in CHIKV-endemic areas.

78 RDTs have become available for detecting CHIKV and are reported to have variable
79 performance and operational characteristics [4–6]. Much remains unknown regarding how

80 these tests increase the efficiency of the health systems if introduced appropriately, how
81 acceptable they are for patients and health care providers, and how cost-effective they are,
82 given the poor state of many countries' economies primarily impacted by CHIKV. Thus, we
83 aim to (i) identify the extent of research on CHIKV RDTs; (ii) provide a comprehensive
84 landscape of CHIKV RDTs available globally; (iii) evaluate the performance of CHIKV RDTs for
85 the diagnosis of CHIKV in symptomatic individuals when compared with a reference
86 standard, and (iv) identify knowledge gaps and further research related to CHIKV RDTs.

87 **Methods**

88 We followed the PRISMA Extension for Scoping Reviews (Prisma-ScR) guidance from the
89 EQUATOR (Enhancing the QUALity and Transparency Of health Research) Network [7]. The
90 Prisma-ScR checklist is available in the Supplementary material.

91 **Eligibility criteria**

92 Search terms were based on a PICO (population, intervention, comparator, and outcome)
93 framework. The population encompassed symptomatic febrile individuals suspected of
94 CHIKV infection. The intervention used CHIKV RDTs, either in developmental or
95 commercially available, to diagnose CHIKV infection, with the comparator being a validated
96 laboratory-based RT-PCR or ELISA assay. The primary outcome was the accuracy of the
97 CHIKV RDT when compared with reference assays.

98 Articles were excluded if (i) the studies were reviews, case reports, or opinion articles; (ii)
99 the studies evaluated the performance of reverse transcription loop-mediated isothermal
100 amplification (RT-LAMP) assays; (iii) the studies were related to an outbreak investigation
101 without the evaluation of the accuracy of CHIKV RDTs; (iv) the studies used an inappropriate
102 study population (asymptomatic individuals); (v) the studies described inappropriate

103 reference assays to assign true positive/true negative status to study samples; and (vi)
104 studies that were related to other arboviruses.

105 **Operational definitions**

- 106 • CHIKV RDT was defined as a rapid (≤ 60 min) point-of-care (POC) assay that requires
107 minimal instrumentation to provide actionable results.
- 108 • We classified the stage of CHIKV RDT assay development in four phases: phase I,
109 which consist of the prototype evaluation process; phase II evaluation under ideal
110 conditions using convenience or archived samples; phase III evaluations under ideal
111 conditions assessing the performance and operation characteristics of the index test
112 in a target population; and phase IV which are assessments of the impact of
113 diagnostics on the prevalence of infection, the incidence of infection, or incidence of
114 complications.

115 **Information sources**

116 Medline, EMBASE, and Scopus electronic databases were searched from inception to 13
117 October 2021 to identify relevant publications in peer-reviewed journals as original scientific
118 research. Additional studies were identified through manual searches of the reference lists
119 of identified papers. The electronic database search was supplemented by searching at
120 major tropical medicine conference abstracts repositories and the manufacturer's official
121 website to seek relevant unpublished reports. The final search results were exported into
122 Mendeley to manage citations identified.

123 In order to provide a comprehensive assessment of diagnostic products that are in the
124 developmental phase and commercialization, we conducted searches in national regulatory
125 agencies (i.e., European Medicines Agency, U.S. Food and Drug Administration, and the

126 Brazilian National Health Surveillance Agency) websites looking for registered CHIKV RDTs
127 and a free search through the Google search engine.

128 **Search**

129 The search in Medline was performed using the following terms: (chikungunya OR
130 “chikungunya virus” OR “chikungunya fever”) AND (“rapid diagnostic test” OR “rapid test”).

131 There was no language or time restriction. After deleting duplicates, the literature review
132 group systematically screened the title, abstract and full text of each study’s inclusion and
133 exclusion criteria.

134 **Data charting process**

135 Data were extracted independently from the selected studies by two authors and recorded
136 into a standard form designed for this study. Discrepancies were resolved by mediation and
137 discussion with other reviewers if needed. The standardized data abstraction tool captured
138 the relevant information on key study characteristics and detailed information on all metrics
139 used to estimate the accuracy of the CHIKV RDTs. Key variables that were systematically
140 extracted include the year of investigation, geographical location, study design, type of RDT
141 assay, time of illness onset to testing, reference assay, sample size, and diagnostic accuracy
142 parameters (if available). If a study evaluated more than one RDT assay, we extracted the
143 data related to each assay type. When articles did not provide sufficient information on
144 relevant data, we contacted the authors via email for additional information.

145 **Critical appraisal of individual sources of evidence**

146 The quality of each diagnostic accuracy study was assessed following QUADAS-2 guidelines
147 [8].

148 **Synthesis of results**

149 Data from all studies were aggregated, and frequency statistics were run to describe the
150 population across all studies. Tableau Desktop Professional Edition (Tableau software, LLC,
151 version 2021.1.0, Seattle, Washington, US) and GraphPad Prism (GraphPad Software,
152 version 8.0, San Diego, California, U.S.) were used to represent the evidence visually.

153 **Results**

154 **Search results**

155 The initial search identified 271 potential studies for evaluation (Supplementary Figure 1).
156 After duplicates were removed, a total of 185 citations were identified from searches of
157 electronic databases. Based on the title and the abstract, 96 were excluded, with 89 full-text
158 articles retrieved and assessed for eligibility. The remaining 18 studies were considered
159 eligible for this review (all apart from one reported diagnostic accuracy metric).

160 **Description of studies**

161 A summary of the included studies is shown in Table 1. The main countries where the
162 CHIKV patients were sourced were India (3/18 studies, 16.6%), Thailand (3/18 studies,
163 16.6%), Indonesia (2/18 studies, 11.1%), and Aruba (2/18 studies, 11.1%) [Supplementary
164 Figure 2]. CHIKV RDTs studies were phase I (7/18 studies, 38.8%) and II (7/18 studies, 38.8%)
165 in most included studies. Three studies were phase III [4,9]. No study was phase IV. Sample
166 recruitment used case-control methodologies (13/18 studies, 72.2%), a prospective cohort
167 design (4/18 studies, 22.2%), or described the development of a pilot RDT assay (1/18
168 studies, 5.5%)[10]. Description of the tested population and the setting where they were
169 applied was almost absent in the studies.

170 **Global availability of Chikungunya RDTs**

171 Table 2 shows the characteristics of CHIKV RDTs developed or commercialized for POC
172 applications. The countries that manufacturer the most CHIKV RDTs were Brazil ($n=17$),
173 followed by the USA ($n=7$), South Korea ($n=7$), and India ($n=6$) [Figure 1].

174 Overall, the CHIKV RDT market is fragmented, but the manufacturer with the most products
175 in the market is Chembio Diagnostics Brazil ($n= 5$ products) and SD BIOSENSOR ($n=3$
176 products) [Table 3]. Almost all assays are antibody-based RDTs ($n=43$) designed in an
177 immunochromatographic format. There were neither antigen-based RDTs nor a
178 combination of antibody and antigen-based RDTs commercially available. Our searches for
179 approved assays in national regulatory authorities did not find any assay registered by the
180 European Medicines Agency or the U.S. Food and Drug Administration. Conversely, the
181 Brazilian National Health Surveillance Agency (ANVISA) has approved 23 CHIKV RDTs for
182 clinical use. Of these, 5/23 (21.7%) were multiplex assays with targets concomitant for
183 Dengue and Zika analytes. Supplementary Table 1 shows the characteristics of CHIKV RDTs
184 approved by the ANVISA.

185 **Diagnostic accuracy results**

186 Table 4 shows a summary of the diagnostic assessments included conducted between 2005-
187 2019. In total, 3722 samples were tested with RDTs across all the studies (Supplementary
188 Figure 3). Sample types included whole blood, plasma, and serum. Twelve studies examined
189 the performance of antibody-based RDTs [11][12][13][14][15][16][17][9,18][19][9] while
190 five the antigen-based RDTs [20][21][22][5][23].

191 The predominant CHIKV RDT assay evaluated in the studies was the OnSite® Chikungunya
192 IgM Combo Rapid test (CTK Biotech, Inc., Poway, CA, USA) in 8/17 (47%) studies, followed by
193 the SD BIOLINE Chikungunya IgM test (Standard Diagnostics Inc., Yongin-si, South Korea) in
194 3/17 (17.6%) studies. The most of antibody RDTs studies target IgM, while four studies

195 target both IgM and IgG immunoglobulin components. Figure 2 shows the diagnostic
196 accuracy for the OnSite® Chikungunya IgM Combo Rapid test and SD BIOLINE Chikungunya
197 IgM test.

198 Overall, the sensitivity of the RDT IgM component typically ranged between 20% and 100%.
199 The sensitivity of the RDT IgG component ranged from 5-100%. The RDT IgM and the IgG
200 specificity ranged from 77.6-100% and 85.4-100%, respectively. Interestingly, some studies
201 reported an increase in the overall sensitivity of antibody-based RDT over time [[4][15].

202 There are two types of antigen-based RDTs evaluated – E1 and E1/E2-antigens tests. The
203 sensitivity of the E1-antigen tests ranged from 33.3 to 100%. Conversely, the specificity
204 varied between 83.1-100%.

205 **Risk of bias assessment**

206 Figure 3 summarizes the QUADAS-2 assessment by study. There were patient selection
207 applicability concerns for most of the study ($n=14$) because there was a lack of sufficient
208 information reported in the studies regarding the patient population, demographic features,
209 setting of the study, or presence of co-morbidities. Similarly, there was a high risk of bias in
210 the patient selection domain because only three studies enrolled a consecutive or random
211 sample of eligible patients with suspicion of CHIKV infection to reduce the bias in the
212 diagnostic accuracy of the index test.

213 **Discussion**

214 **Summary of evidence**

215 This scoping review identified 18 studies conducted between 2005 and 2019, addressing the
216 research stage on CHIKV RDTs across various settings. Our findings indicate a paucity of
217 research focusing on field trials and implementation studies related to CHIKV RDTs. Our
218 work provides a global view of publicly available data on CHIKV RDTs currently under

219 development or commercially available. We also found that the in vitro diagnostic medical
220 device manufacturers are primarily concentrated on CHIKV antibody RDTs, and their
221 accuracy overall performs poorly and should not be used in clinical settings as long as they
222 suffer significant improvements [15][4]. Conversely, antigen RDTs, although still in a
223 development phase, promise to have a high level of sensitivity and specificity across the
224 distinct CHIKV genotypes [5][22].

225 Given the problems associated with the existing diagnostic strategies for CHIKV, there is a
226 clear and urgent need for new, appropriate diagnostic tools for CHIKV that meet the ideal
227 product profile of “REASSURED” diagnostics [24]. The characteristics of the diagnostics
228 products mentioned above are defined by a set of criteria which includes: (i) Real-time
229 connectivity; (ii) Ease of specimen collection; (iii) Environmental friendliness; (iv) Affordable
230 by those at risk of infection; (v) Sensitive (few false-negatives); (vi) Specific (few false-
231 positives); (vii) User-friendly (simple to perform and requiring minimal training); (viii) Rapid
232 (to enable treatment at first visit) and Robust (does not require refrigerated storage); (xi)
233 Equipment-free; and (x) Delivered to those who need it. Few products right now meet the
234 ideal “REASSURED” profile, and new research and investments are required to develop
235 those that match the profile needed. Pertinent questions about feasibility, acceptability,
236 cost-effectiveness, sustainability, and policy implications must be addressed before the
237 widespread use of CHIKV RDTs in endemic countries. More importantly, we also need to
238 address the impact of CHIKV RDTs into integrated fever case management and how its
239 implementation translates into a better prescription practice for acute febrile patients (i.e.,
240 reducing unnecessary antibiotic prescription).

241 The CHIKV RDTs diagnostic landscape is fragmented, with many gaps along the development
242 pathway. Figure 4 shows our proposed conceptual framework that delineates the challenges

243 and opportunities across each stage of CHIKV RDT development. Concerted efforts leading
244 by different stakeholders (i.e., international donors, industry, public sector, and end-users)
245 should be put together to bring more equity to the availability of appropriate CHIKV RDTs to
246 those needed most.

247 **Limitations**

248 Our work has limitations. Although we made a herculean effort to identify the highest
249 numbers of CHIKV RDTs manufactured or commercially available in the market, we
250 understand that some could not be identified and were not publicly available. However, we
251 addressed this bias by looking into CHIKV RDTs that national/regional regulatory agencies
252 have approved or those that provided data from unpublished sources (i.e., conference
253 abstracts, manufacturers' reports, author's unpublished data). Next, we did not provide an
254 effect estimate for the results of diagnostic accuracy studies, because as shown in our risk of
255 bias assessment, the studies included were very heterogeneous, and a meta-analytic
256 approach would be useless.

257 **Conclusions**

258 Our scoping review demonstrated substantial gaps in the current diagnostic landscape of
259 CHIKV RDTs. The future needs of immunoassay-based RDTs for CHIKV are summarized in
260 Box.

261 The time is suitable for a collaborative, focused initiative between policy-makers and other
262 relevant stakeholders to address the urgent need for new, appropriate CHIKV RDTs.
263 Unprecedented opportunities for market interventions exist and utilize new technologies to
264 make a significant, measurable impact. Further research is desperately needed to facilitate
265 the incorporation of CHIKV RDTs into integrated fever algorithms, and socio-behavioral
266 research should be done to evaluate end-user acceptability.

Box. Future needs of immunoassay-based RDTs for CHIKV infection

Market needs

- Foster the development of antigen-based RDTs should significantly enhance assays sensitivity in the first days of illness onset

Regulatory needs

- Work to harmonize diagnostic accuracy evaluations so that there is comparability between studies
- World Health Organization (WHO) Pre-Qualification scope as well as the WHO Essential Diagnostic List would need to be expanded to include CHIKV RDTs, as is the case for Dengue and Zika. This would ensure that potential buyers/end-users at low-resource countries, identified quality-assured CHIKV RDTs

Technical needs

- More evidence is needed to clarify the performance of CHIKV RDT assays in samples collected from distinct regions of the globe where different CHIKV lineages circulate. The first-generation of antigen-based RDTs had performance greatly influenced by the genotype

Operational needs

- Examine the operational characteristics of different RDTs when tested at high temperatures (> 30°C), commonly found in CHIKV-endemic regions. Other aspects should also be evaluated: the impact of samples other than serum, the influence of extensive reading times (> 20 min), and the effect of prozone phenomena

267

268

269 **Contributions**

270 All authors critically reviewed the manuscript, gave their final approvals, and are accountable
271 for accuracy and integrity.

272 **Acknowledgments**

273 J.M. received a scholarship from Fundacao de Amparo a Pesquisa do Estado do Rio de
274 Janeiro (FAPERJ) for his Ph.D. study in Brazil.

275

276 **Funding**

277 This work has not received any funding

278 **Conflicts of interest**

279 None to declare

280 **References**

- 281 1. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne
282 disease. *N Engl J Med. United States*; 2015;372:1231–9.
- 283 2. Leta S, Beyene TJ, De Clercq EM, Amenu K, Kraemer MUG, Revie CW. Global risk mapping
284 for major diseases transmitted by *Aedes aegypti* and *Aedes albopictus*. *Int J Infect Dis IJID*
285 *Off Publ Int Soc Infect Dis.* 2018;67:25–35.
- 286 3. Kerkhof K, Falconi-Agapito F, Van Esbroeck M, Talledo M, Ariën KK. Reliable Serological
287 Diagnostic Tests for Arboviruses: Feasible or Utopia? *Trends Microbiol [Internet]*. K.K. Ariën,
288 Department of Biomedical Sciences, Unit of Virology, Institute of Tropical Medicine,
289 Antwerp, Belgium; 2020;28:276–92. Available from:
290 [https://www.embase.com/search/results?subaction=viewrecord&id=L2004290661&from=e](https://www.embase.com/search/results?subaction=viewrecord&id=L2004290661&from=export)
291 [xport](#)
- 292 4. Rianthavorn P, Wuttirattanakowit N, Prianantathavorn K, Limpaphayom N,
293 Theamboonlers A, Poovorawan Y. Evaluation of a rapid assay for detection of IgM
294 antibodies to chikungunya. *Southeast Asian J Trop Med Public Health. Thailand*;
295 2010;41:92–6.
- 296 5. Suzuki K, Huits R, Phadungsombat J, Tuekprakhon A, Nakayama EEEE, Van Den Berg R, et
297 al. Promising application of monoclonal antibody against chikungunya virus E1-antigen
298 across genotypes in immunochromatographic rapid diagnostic tests. *Viol J.* 2020;17:90.
- 299 6. Huits R, Okabayashi T, Cnops L, Barbé B, Van Den Berg R, Bartholomeeusen K, et al.

- 300 Diagnostic accuracy of a rapid E1-antigen test for chikungunya virus infection in a reference
301 setting. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. England*;
302 2018;24:78–81.
- 303 7. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for
304 Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med. United States*;
305 2018;169:467–73.
- 306 8. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2:
307 a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med.*
308 *United States*; 2011;155:529–36.
- 309 9. Mistretta M, Bonafini S, Angheben A, Gobbo M, Tais S, Bisoffi Z. Assessment of a Rapid
310 Diagnostic Test for Chikungunya. *Trop Med Int Heal [Internet]*. M. Mistretta, Ospedale
311 Sacrocuore, Centre for Tropical Diseases, Negrar (Verona), Italy; 2009;14:227. Available
312 from:
313 [https://www.embase.com/search/results?subaction=viewrecord&id=L70253091&from=exp](https://www.embase.com/search/results?subaction=viewrecord&id=L70253091&from=export)
314 [ort](https://www.embase.com/search/results?subaction=viewrecord&id=L70253091&from=export)
- 315 10. Lee S, Mehta S, Erickson D. Two-Color Lateral Flow Assay for Multiplex Detection of
316 Causative Agents behind Acute Febrile Illnesses. *Anal Chem.* 2016;88:8359–63.
- 317 11. Lee H, Ryu JH, Yun S, Jang JH, Choi AR, Cho SY, et al. Evaluation of a Newly Developed
318 Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect IgG and IgM Antibodies
319 to Chikungunya Virus. *Infect Chemother.* 2020;52:611–5.
- 320 12. WON-Shik Kim, Yong-Gyoo Lee, Man Kyu Huh YL. CHIKUNGUNYA VIRUS INFECTION
321 EVALUATION USING RAPID DIAGNOSTIC TESTS (RDTS) BASED ON ANTI-CHIKUNGUNYA
322 IGM/IGG. *Eur J Pharm Med Res.* 2019;6:30–5.
- 323 13. Burdino E, Calleri G, Caramello P, Ghisetti V. Unmet Needs for a Rapid Diagnosis of

- 324 Chikungunya Virus Infection. *Emerg. Infect. Dis.* 2016. p. 1837–9.
- 325 14. Prat CM, Flusin O, Panella A, Tenebray B, Lanciotti R, Leparç-Goffart I. Evaluation of
326 commercially available serologic diagnostic tests for chikungunya virus. *Emerg Infect Dis.*
327 2014;20:2129–32.
- 328 15. Kosasih H, Widjaja S, Surya E, Hadiwijaya SH, Butarbutar DPR, Jaya U.A., et al. Evaluation
329 of two IgM rapid immunochromatographic tests during circulation of Asian lineage
330 Chikungunya virus. *Southeast Asian J Trop Med Public Health. Thailand*; 2012;43:55–61.
- 331 16. Arya SC, Agarwal N. Rapid point-of-care diagnosis of chikungunya virus infection. *Asian*
332 *Pacific J Trop Dis* [Internet]. S.C. Arya, Sant Parmanand Hospital, 18 Alipore Road, Delhi-
333 110054, India; 2011;1:230–1. Available from:
334 [https://www.embase.com/search/results?subaction=viewrecord&id=L364263335&from=ex](https://www.embase.com/search/results?subaction=viewrecord&id=L364263335&from=export)
335 [port](https://www.embase.com/search/results?subaction=viewrecord&id=L364263335&from=export)
- 336 17. Yap G, Pok K-YK-Y, Lai Y-LY-L, Hapuarachchi H-CH-C, Chow A, Leo Y-SY-S, et al. Evaluation
337 of Chikungunya diagnostic assays: differences in sensitivity of serology assays in two
338 independent outbreaks. *PLoS Negl Trop Dis.* 2010;4:e753.
- 339 18. Johnson BW, Goodman CH, Holloway K, De Salazar PM, Valadere AM, Drebot MA.
340 Evaluation of commercially available Chikungunya Virus Immunoglobulin M detection
341 assays. *Am J Trop Med Hyg.* 2016;95:182–92.
- 342 19. Wang R, Ongagna-Yhombi SY, Lu Z, Centeno-Tablante E, Colt S, Cao X, et al. Rapid
343 Diagnostic Platform for Colorimetric Differential Detection of Dengue and Chikungunya
344 Viral Infections. *Anal Chem.* 2019;91:5415–23.
- 345 20. Huits R, Okabayashi T, Cnops L, Barbé B, Van Den Berg R, Bartholomeeusen K, et al.
346 Diagnostic accuracy of a rapid E1-antigen test for chikungunya virus infection in a reference
347 setting. *Clin Microbiol Infect.* 2018;24:78–81.

- 348 21. Okabayashi T, Sasaki T, Masrinoul P, Chantawat N, Yoksan S, Nitatpattana N, et al.
349 Detection of chikungunya virus antigen by a novel rapid immunochromatographic test. *J Clin*
350 *Microbiol.* 2015;53:382–8.
- 351 22. Jain J, Okabayashi T, Kaur N, Nakayama E, Shioda T, Gaird R, et al. Evaluation of an
352 immunochromatography rapid diagnosis kit for detection of chikungunya virus antigen in
353 India, a dengue-endemic country. *Virology*. 2018;15.
- 354 23. Reddy A, Bosch I, Salcedo N, Herrera BB, de Puig H, Narváez CF, et al. Development and
355 Validation of a Rapid Lateral Flow E1/E2-Antigen Test and ELISA in Patients Infected with
356 Emerging Asian Strain of Chikungunya Virus in the Americas. *Viruses*. 2020;12.
- 357 24. Land KJ, Boeras DI, Chen X-S, Ramsay AR, Peeling RW. REASSURED diagnostics to inform
358 disease control strategies, strengthen health systems and improve patient outcomes. *Nat*
359 *Microbiol.* 2019;4:46–54.
- 360
- 361
- 362
- 363
- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371

372 **Figure legend**

373 Figure 1. Number of Chikungunya rapid diagnostic tests developed or commercialized for
374 point-of-care application by country of manufacture

375 Figure 2. Summary of diagnostic accuracy studies evaluating the OnSite® Chikungunya IgM
376 Combo Rapid test (CTK Biotech, Inc., Poway, CA, USA) and the SD BIOLINE Chikungunya IgM
377 test (Standard Diagnostics Inc., Yongin-si, South Korea)

378 Figure 3. QUADAS-2 assessment of studies

379 Figure 4. Chikungunya rapid diagnostic tests: Fragmented landscape presents market
380 challenges and opportunities for interventions

381

382

383

384

385

386

387

388

389

390

391

392


393

394

395


396 **Figure 1**

Number of Chikungunya rapid diagnostic tests developed or commercialized for point-of-care application by country of manufacture



Assumptions: All data represents publicly available information. The location of the diagnostic manufacturer is currently assumed to be the manufacturing headquarters, not necessarily where the Chikungunya RDT is being manufactured.

Number of Chikungunya RDT by country



397

398

399

400

401

402

403

404

405

406

407

408

409

410


411

412

413

414


415 **Figure 2**
416



417
418
419
420
421
422
423
424
425
426


- A. OnSite® Chikungunya IgM Combo Rapid test (CTK Biotech, Inc., Poway, CA, USA) sensitivity across the studies
- B. OnSite® Chikungunya IgM Combo Rapid test (CTK Biotech, Inc., Poway, CA, USA) specificity across the studies
- C. SD BIOLINE Chikungunya IgM test (Standard Diagnostics Inc., Yongin-si, South Korea) sensitivity across the studies
- D. SD BIOLINE Chikungunya IgM test (Standard Diagnostics Inc., Yongin-si, South Korea) specificity across the studies

427 **Figure 3**
428



429


■ Low ■ High ■ Unclear



Proportion of studies with low, high, or unclear CONCERNS regarding APPLICABILITY

430
431
432
433

434 Figure 4. Chikungunya rapid diagnostic tests: Fragmented landscape presents market
 435 challenges and opportunities for interventions
 436
 437



438
 439 CHIKV chikungunya virus; RDT rapid diagnostic test; EDL World Health Organization'
 440 Essential diagnostic list; IMDRG International Medical Devices Regulatory Forum; IVD in-
 441 vitro diagnostic products; PPP Public-Private Partnership; P.Q. World Health Organization'
 442 in-vitro diagnostic pre-qualification program; R&D Research & Development; TPP target
 443 product profile; WHO World Health Organization

444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471

472 Table.1 Characteristics of included studies evaluating Chikungunya antibody or antigen-based rapid diagnostic tests, 2005-2019.
 473
 474

First author, year [Reference]	Location	Study design	Assay	Assay's phase of diagnostic development	Setting	Age (years)	Severity
Moreira J et al. 2021 unpublished	Brazil	Prospective recruitment	DPP® ZCD IgM/IgG	Phase III	Primary care	26 [IQR: 15-41]	Non-severe
Reddy A et al. 2020 [23]	Honduras & Colombia	Case-control	E1/E2-Antigen test	Phase I	ND	ND	ND
Suzuki et al. 2020 [5]	Aruba & Bangladesh	Case-control	E1-Antigen test	Phase I	ND	ND	ND
Lee H et al. 2020 [11]	ND	Case-control	ichroma® Chikungunya virus (IgG/IgM)	Phase II	ND	ND	ND
Kim WS et al. 2019 [12]	ND	Case-control	Chikungunya IgM/IgG (GenBody)	Phase II	ND	ND	ND
Wang R et al. 2019 [19]	Colombia	Case-control	DENV IgG/IgM CHIKV IgG/IgM	Phase I	ND	18-74	ND
Huits R et al. 2018 [20]	Mauritius, Réunion, India, Thailand, French Polynesia, Aruba	Case-control	E1-Ag test	Phase I	ND	ND	ND
Jain J et al. 2018 [22]	India	Case-control	E1-Ag test	Phase I	ND	ND	ND
Lee S et al. 2016	ND	Development	DENV IgG/IgM	Phase I	ND	ND	ND

[10] Burdino E et al. 2016 [13]	Caribbean & Latin America	study Prospective recruitment	CHIKV IgG/IgM OnSite® Chikungunya IgM Combo Rapid test	-	ND	ND	ND
Johnson BW et al. 2016 [18]	ND	Case-control	OnSite® CHIKV IgM Combo Rapid test SD BIOLINE Chikungunya IgM	Phase II	ND	ND	ND
Okabayashi T et al. 2015 [21]	Thailand, Laos, Indonesia, and Senegal	Case-control	E1-Ag test	Phase I	ND	ND	ND
Prat CM et al. 2014 [14]	ND	Case-control	SD BIOLINE Chikungunya IgM OnSite® Chikungunya IgM Combo Rapid tes	Phase II	ND	ND	ND
Kosasih H et al. 2012 [15]	Indonesia	Case-control	OnSite® Chikungunya IgM Rapid test SD BIOLINE Chikungunya IgM test	Phase II	ND	ND	ND
Arya SC et al. 2011 [16]	India	Case-control	OnSite® Chikungunya IgM Rapid test	Phase II	ND	ND	ND

Yap G et al. 2010 [17]	Singapore	Case-control	OnSite® Chikungunya IgM Combo Rapid test	Phase II	ND	ND	Severe
Rianthavorn P et al. 2010 [4]	Thailand	Prospective recruitment	OnSite® Chikungunya IgM Combo Rapid test	Phase III	ND	ND	ND
Mistretta M et al. 2009 [9]	Italy	Prospective recruitment	OnSite® Chikungunya IgM Combo Rapid test	Phase III	ND	ND	ND

475 ICT immunochromatographic assay; IQR interquartile range; ND not described

476 Phases of diagnostics developments are classified in 4 phases: phase I which consist of prototype evaluation process; phase II evaluation under
 477 ideal conditions using convenience or archived samples; phase III evaluations under ideal conditions assessing the performance and operation
 478 characteristics of product in target populations; and phase IV which are assessments of impact of diagnostics on prevalence of infection,
 479 incidence of infection, or incidence of complications

480

481

482

483

484

485

486

487

488

489 Table 2. Characteristics of Chikungunya rapid diagnostic tests developed or commercialized for point-of-care application

490

Manufacturer	Manufacturer	Product	Analytes	Quoted	Storage	Sample	Format	Sample	Reading
--------------	--------------	---------	----------	--------	---------	--------	--------	--------	---------

	country	name		accuracy (Sn/Sp)	temperature (°C)			volume (uL)	time (min)
ARKRAY, Inc.	Japan	E1-Ag test	E1	NA	NA	S	DS	30	15
Boditech Med Inc.	South Korea	iChroma	IgG/IgM	NA	NA	S, P, W	IC	30	12
Meridian Bioscience, Inc.	USA	TruQuick™ CHIKV IgG/IgM 40 T	IgG/IgM	IgG: 94.3/97 IgM: 90.3/99.9	2-30	S, P, W	IC	40	15
Biotest	China	MedTest Chikungunya ML-02	IgM/IgG	99.9/99.9	2-30	S, P, W	IC	40	15
Oscar Medicare Pvt Ltd	India	Oscar Chikungunya test	IgM/IgG	NA	2-30	S, P	IC	NA	NA
Bio Footprints Healthcare Pvt. Ltd.	India	Mytest One Step Chikungunya IgM Test kit	IgM	NA	NA	S, P	IC	NA	NA
LumiQuick Diagnostics	USA	Chikungunya test kit QuickProfile	IgG/IgM	NA	4-30	S, P, W	IC	NA	NA
INTERMEDICAL	Italy	Chikungunya IgM Rapid Test	IgM	96.9/98.6	2-30	S, P, W	IC	50	15
Neo nostics	China	Chikungunya IgG/IgM Rapid test	IgG/IgM	NA	2-30	S, P, W	IC	NA	NA
Anand Enterprises	India	Chikungunya IgM One Step	IgM	NA	NA	S, P	IC	NA	NA
BIOZEK medical	Netherlands	Chikungunya IgG/IgM Rapid Test Cassette	IgG/IgM	NA	NA	S, P, W	IC	NA	NA
Atlas Link Technology Co., Ltd	China	NOVAtest Chikungunya IgG/IgM Rapid Test Cassette	IgG/IgM	NA	NA	S, P, W	IC	NA	15
SD BIONSENSOR	South Korea	STANDARD Q Chikungunya IgM/IgG	IgM/IgG	IgM: 100/97.6 IgG: 100/99.6	2-40	S, P, W	IC	10	15-20
SD BIONSENSOR	South Korea	STANDARD F Chikungunya IgM/IgG FIA	IgM/IgG	NA	2-30	S, P, W	FIA		15
SD BIONSENSOR	South Korea	STANDARD Q Arbo Panel I (Z/D/C/Y)	IgM (ZIKV, DENV, CHIKV, YFV), DENV NS1	NA	2-40	S, P, W	IC	10-100	15-20

Tulip Diagnostics Ltd.	India	INSIGHT Chikv	IgM		4-30	S, W		5-10	15
Biopanda Reagents	UK	Chikungunya IgG/IgM Rapid Test	IgG/IgM	IgG: 94.3/97 IgM: 90.3/99.9	2-30	S, P, W	IC		15
GenBody Inc.	South Korea	Chikungunya IgM/IgG	IgM/IgG	IgM: 97.1/98.5 IgG: 98/98	2-30	S, P, W	IC	30-60	15-20
BHAT Bio-Scan	India	Chikungunya IgM Spot Test	IgM	NA	2-8	S, P	IC	NA	15
Acro Biotech, Inc	USA	Immunoassay Ivd Chikungunya Rapid Diagnostic Test kit	IgG, IgM	NA	NA	S, P, W	IC	NA	NA
J. Mitra & Co. Pvt. Ltd.	India	Advantage Chikungunya IgM Card	IgM	97.5/99.1	2-30	S, P, W	IC	70	15
JP BioGen Diagnostics Ltd	Greece	Chikungunya IgM TES	IgM	97.1/91.1	NA	S, P, W	IC	50-100	10
ICT diagnostics	South Africa	Chikungunya IgG/IgM Rapid Test Cassette	IgG/IgM	IgG: 94.3/97 IgM: 90.3/99.9	2-40	S, P, W	IC	40	15
Diagnostic Automation/Cortez Diagnostics, Inc.	USA	OneStep Chikungunya IgG/IgM Combo RapiCard™ InstaTest	IgG, IgM	NA	4-30	S, P, W	IC	5	15
HWTai BioTec	China	Rapid chikungunya test	IgM	NA	NA	S, P, W	IC	NA	NA
Teco Diagnostics	USA	Chikungunya IgM	IgM	NA	NA	S, P, W	IC	NA	NA
Biocan diagnostics, Inc.	Canada	Chikungunya IgG/IgM Ab Rapid Test	IgG/IgM	NA	NA	S, P, W	IC	NA	NA
Biocan Diagnostics, Inc.	Canada	Zika IgG/IgM Ab, Dengue IgG/IgM & NS1 Ag & Chikungunya IgG/IgM Ab Combo Test	IgM, IgG, NS1	NA	NA	S, P, W	IC	NA	NA
Bioditech Med	South Korea	ichroma CHIKV IgG/IgM	IgG, IgM	NA	NA	S, P, W	IC	30	12
Standard Diagnostics Inc.	South Korea	SD Bioline Chikungunya IgM	IgM	97.1/98.9	1-30	S, P, W	IC	50-100	10

CTK Biotech Inc.	USA	OnSite™ Chikungunya IgM Combo Rapid Test	IgM	90.4/98	2-30	S, P, W	IC	5	15
Chembio Diagnostics, Inc.	USA	DPP® Chikungunya IgM/IgG assay	IgM/IgG	NA	2-30	S, P, W	IC	10	15
Bio-Manguinhos	Brazil	DPP® ZCD IgM/IgG	IgM,IgG	IgM: 100/99.4 IgG: 100/100	2-30	S, P, W	IC	10	15
Orange Life	Brazil	OL Combo Chikungunya /NS1	DENV NS1/CHIKV IgM	NS1:92.8/98.4 IgM: 98.5/99.5	NA	S, P, W	IC	NA	15-20
Orange Life	Brazil	OL Combo Chikungunya Dengue -IgG/IgG	DENV IgM/IgG CHIKV IgM	DENV IgM/IgG: 99.5/98.5 CHIKV IgM: 98.5/99.5	NA	S, P, W	IC	NA	15-20
Orange Life	Brazil	OL Chikungunya IgM	IgM	98.5/99.5	NA	S, P, W	IC	NA	15-20
Orange Life	Brazil	OL Chikungunya IgG/IgM	IgM/IgG	IgM/IgG: 98.5/98.5	NA	S, P, W	IC	NA	15-20
Eco Diagnostica	Brazil	Chikungunya IgG/IgM ECO Test	IgG/IgM	IgG: 100/99.6 IgM: 100/97.6	2-30	S, P, W	IC	10	15
Eco Diagnostica	Brazil	Chikungunya IgM ECO Test	IgM	90.3/100	2-30	S, P, W	IC	30-45	15
Bahiafarma	Brazil	Chikungunya IgM RDT	IgM	94/95	2-30	S, P, W	IC	30-60	10
Ebram Ltda.	Brazil	Chikungunya IgG/IgM	IgG/IgM	IgG: 94.3/97 IgM: 90/99.9	2-30	S, P, W	IC	40	15-20
WAMA Diagnostica	Brazil	Immuno-Rapido Chikungunya IgG/IgM	IgG/IgM	IgG: 100/99.3 IgM:100/97.9	2-30	S, P, W	IC	10	15-20
Biocon diagnosticos	Brazil	Chikungunya Test (IgG/IgM)	IgG/IgM	IgG: 94.3/97 IgM: 90.3/99	NA	S, P	IC	NA	15
Biocon diagnosticos	Brazil	Chikungunya IgM Test	IgM	96.6/98	NA	W	IC	NA	15


491 S serum; P plasma, W whole blood; IC Immunochromatographic assay; FIA fluorescent immunoassay; DS dipstick NA not available

492 Sn/sp: sensitivity/specificity

493 Table 3. Global Chikungunya rapid diagnostic tests landscape – key players on industry

494

Global Chikungunya rapid diagnostic tests landscape - key players on industry



495

496
497

Table 4. Summary of diagnostic assessments of Chikungunya antibody or antigen-based rapid diagnostic tests, 2005-2019.

Assay	Study	Year	Sample size	Time from symptom onset to testing (days)	Reference comparator	Analyte target	Sensitivity (95% CI)	Specificity (95% CI)
Antibody-based rapid diagnostic test								
DPP® ZCD IgM/IgG								
	Moreira J et al. 2021	2018-2019	500	3 (IQR: 2-4)	Euroimmun IgM/IgG ELISA	igM	23.2 (15.3-32.7)	77.6 (71-83.4)
					RT-PCR	igG igM/IgG	5 (1.6-11.2) 24 (16-33.5)	85.4 (79.6-90) 75.1 (68.4-81)
ichroma® Chikungunya virus (IgG/IgM)								
	Lee H et al. 2020	ND	256	ND	Inbios IgM/IgG ELISA	igM igG	100 (94.7-100) 100 (92.4-100)	99.4 (97.5-99.4) 100 (98.3-100)
Chikungunya IgM/IgG (GenBody)								
	Kim WS et al. 2019	2014	770	ND	ELISA	igM	83	97
					RT-PCR	igG	100	100
Multiplex RDT (under development)								
	Wang R et al. 2019	ND	50	ND	Euroimmun ELISA	igM igG	83 100	97 100
OnSite® Chikungunya IgM Rapid Test								
	Burdino E et al. 2016	2014-2015	8	7-30	Euroimmun IgM/IgG IFA	igM	37.5	100
					RT-PCR			

Prat CM et al. 2014	2005-2014	23	ND	In-house IgM/IgG ELISA In-house neutralization test	IgM	20	93
Kosasih H et al. 2012	ND	132	1 to \geq 21	In-house IgM ELISA RT-PCR	IgM	20.5	100
Arya SC et al. 2011	2010	100		IgM ELISA	IgM	35.7	NA
Yap G et al. 2010	2008	225	3.75 to $>$ 7	IgM IFA In-house IgM ELISA RT-PCR	IgM	12.1	100
Mistretta M et al. 2009	2006-2008	116	ND	Euroimmun IFA	IgM	85	95
Johnson BW et al. 2016	ND	27	2-33	CDC in-house MAC-ELISA	IgM	13.04 (2.78-33.59)	100 (39.76-100)
SD Bioline Chikungunya IgM test							
Prat CM et al. 2014	2005-2014	23	ND	In-house IgM/IgG ELISA In-house neutralization test	IgM	30	73
Kosasih H et al. 2012	ND	132	1 to \geq 21	In-house IgM ELISA RT-PCR	IgM	50.8	89.2
Rianthavorn P et al. 2010	2008	527	1 to \geq 14	SD Bioline IgM ELISA RT-PCR	IgM	37	85
Johnson BW et al. 2016	ND	31	2-33	CDC in-house MAC ELISA	IgM	0	100 (59-100)
Antigen-based rapid diagnostic tests							
E1-Antigen test							
Huits R et al.	2006-	98	\leq 10	ECSA & Asian	E1-antigen	88.9 (56.5-98)	83.1 (71.5-

	2018	2014-2015			genotype CHIKV-specific RT-PCR Euroimmun IgM/IgG IFA		for the ECSA genotype 33.3 (19.2-51.2) for the Asian genotype	90.5)
	Okabayashi T et al. 2015	2008-2013	112	1-14	ECSA, Asian and West African genotype CHIKV-specific RT-PCR Nova Tec IgM ELISA	E1-antigen	91.2 for the ECSA genotype 89.4 for the overall genotypes	93.8 for the ECSA genotype 94.4 for the overall genotypes
	Jain J et al. 2018	2016	123	1-15	IgM ELISA RT-PCR	E1-antigen	93.7	95.5
	Suzuki K et al. 2020	2014-2018	280	≤ 7	IgM ELISA RT-PCR	E1-antigen	92	100
E1/E2- lateral flow antigen test								
	Reddy A et al. 2020	ND	189	1-5	RT-PCR	E1/E2-antigen	62.5-100 for Honduras' AB combination A 62.5-100 for Honduras' AB combination B 77.7-100 for Colombia' AB combination B	92.3-100 for Honduras' AB combination A 75-100 for Honduras' AB combination B 85.7-100 for Colombia's AB combination B

498
499
500
501
502

503

504